☰

Empresas y finanzas

Key Presentations of Celgene Products to Be Highlighted at the 13th European Hematology Association Congress


    Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers will present data from recent and on–going clinical trials of multiple Celgene products at the 13th European Hematology Association Congress in Copenhagen, Denmark from June 12 - 15, 2008. These presentations will highlight new efficacy and survival results, with important studies highlighting new health economic measures of Celgene therapies.

    Key abstracts include:

    REVLIMID®

    #0229 – TRANSFUSION BURDEN, DISEASE DURATION AND AGE IDENTIFY NON–DELETION 5Q MDS PATIENTS HIGHLY RESPONSIVE TO LENALIDOMIDE TREATMENT - Friday, June 13, 6:45 p.m.

    #0263 – RESULTS FROM A PHASE II STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN RELAPSED OR REFRACTORY INDOLENT NON– HODGKIN´S LYMPHOMA - Friday, June 13, 6:45 p.m.

    #0399 – RESULTS FROM AN INTERNATIONAL STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE IN RELAPSED OR REFRACTORY AGGRESSIVE NON–HODGKIN´S LYMPHOMA - Saturday, June 14, 8:30 a.m.

    #0441 – OVERALL SURVIVAL WITH DEXAMETHASONE IN PHASE III MULTIPLE MYELOMA TRIALS AFTER ADJUSTMENT FOR CROSS–OVER TO LENALIDOMIDE - Saturday, June 14, 10:30 a.m.

    #0714 – RISK FACTORS FOR AML TRANSFORMATION AND MORTALITY IN TRANSFUSION–DEPENDENT DELETION 5Q MDS - Saturday, June 14, 7 p.m.

    #0637 – RESULTS OF A PHASE I/II TRIAL OF DEUTSCHE STUDIENGRUPPE MULTIPLES MYELOM, SHOWING EFFICACY AND SAFETY OF RAD REGIMEN (REVLIMID®, ADRIAMYCIN®, DEXAMETHASONE) IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA - Saturday, June 14, 7 p.m.

    #0804 – ECONOMIC EVALUATION OF LENALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA IN WALES IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY - Saturday, June 14, 7 p.m.

    #0808 – THE ECONOMIC AND SOCIAL BURDEN OF MULTIPLE MYELOMA IN ITALY. THE CO.MI.M STUDY - Saturday, June 14, 7 p.m.

    #0764 – RESULTS FROM A PHASE II TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN RELAPSED OR REFRACTORY AGGRESSIVE NON–HODGKIN´S LYMPHOMA - Saturday, June 14, 7 p.m.

    VIDAZA®

    #0231 – 5–AZACYTIDINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA: RESULTS IN 45 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM - Friday, June 13, 6:45 p.m.

    #0236 – EUROPEAN INTER–COUNTRY TREATMENT SELECTION DIFFERENCES DO NOT ALTER OVERALL SURVIVAL BENEFIT SHOWN WITH AZACITIDINE VS CONVENTIONAL CARE REGIME IN HIGHER–RISK MYELODYSPLATIC SYNDROMES - Friday, June 13, 6:45 p.m.

    #0224 – EFFECT OF AZACITIDINE (AZA) VERSUS LOW–DOSE ARA–C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER–RISK MYELODYSPLASTIC SYNDROMES (MDS) - Friday, June 13, 6:45 p.m.

    #0232 – RAPID ONSET OF EFFECTIVENESS WITH THREE ALTERNATIVE AZACITIDINE (AZA) DOSING REGIMENS IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS) - Friday, June 13, 6:45 p.m.

    #0238 – 5–AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE–2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM - Friday, June 13, 6:45 p.m.

    #0699 – USAGE PATTERNS AND TRANSFUSION REQUIREMENTS IN PATIENTS ENROLLED IN AVIDA, A LONGITUDINAL REGISTRY OF PATIENTS WITH HEMATOLOGIC DISORDERS RECEIVING AZACITIDINE - Saturday, June 14, 7 p.m.

    #1018 "“ EVALUATION OF ERYTHROPOIESIS IN MYELODYSPLASTIC PATIENTS ON AZACITIDINE TREATMENT - Sunday, June 15, 9 a.m.

    #0925 – 5–AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE–1 IPSS RISK MYELODYSPLASTIC SYNDROMES : RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM - Sunday, June 15, 10:30 a.m.

    #0928 – PROLONGED SURVIVAL IN HIGHER–RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH –7/DEL(7Q) TREATED WITH AZACITIDINE (AZA) - Sunday, June 15, 11:15 a.m.

    *All times Central European Summer Time (CEST)

    For more information and for complete abstracts, please visit www.ehaweb.org.

    About Celgene International Sárl

    Celgene International Sárl, located in Boudry, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company´s website at www.celgene.com.

    This release contains certain forward–looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company´s control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward–looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company´s filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.